CIK 0001603756
AXNX Axonics, Inc.
Insider trading from SEC Form 4. Last filing Nov 15, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Axonics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 40 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 15, 2024 | nancy lynn snyderman MD director | DDisposition to issuer Common Stock | -14,944 | $71.00 | $1.1M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Robert McNamara director | DDisposition to issuer Common Stock | -14,861 | $71.00 | $1.1M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Karen Noblett Chief Medical Officer | DDisposition to issuer Common Stock | -34,428 | $71.00 | $2.4M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Esteban Lopez director | DDisposition to issuer Common Stock | -6,600 | $71.00 | $469k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Kari Leigh Keese Chief Financial Officer | DDisposition to issuer Common Stock | -40,362 | $71.00 | $2.9M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Rinda Sama Chief Operating Officer | DDisposition to issuer Common Stock | -83,854 | $71.00 | $6.0M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Alfred J Ford Jr Chief Commercial Officer | DDisposition to issuer Common Stock | -43,450 | $71.00 | $3.1M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | David M Demski director | DDisposition to issuer Common Stock | -9,542 | $71.00 | $677k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | John Woock EVP, Chief Mktg/Strtgy Officer | DDisposition to issuer Common Stock | -77,403 | $71.00 | $5.5M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Raymond W Cohen Chief Executive Officer | DDisposition to issuer Common Stock | -292,731 | $71.00 | $21M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Jane E Kiernan director | DDisposition to issuer Common Stock | -19,861 | $71.00 | $1.4M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Michael H Carrel director | DDisposition to issuer Common Stock | -17,861 | $71.00 | $1.3M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Michael H Carrel director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,000 | $36.90 | $185k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | nancy lynn snyderman MD director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,167 | $36.90 | $154k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Rinda Sama Chief Operating Officer | DDisposition to issuer Common Stockindirect: By Spouse | -608 | $71.00 | $43k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | John Woock EVP, Chief Mktg/Strtgy Officer | DDisposition to issuer Performance-Based Restricted Stock Unitsderivative | -13,125 | $0.00 | $0 | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Karen Noblett Chief Medical Officer | DDisposition to issuer Performance-Based Restricted Stock Unitsderivative | -7,500 | $0.00 | $0 | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Esteban Lopez director | DDisposition to issuer Stock Options (Right to buy)derivative | -10,000 | $11.30 | $113k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Kari Leigh Keese Chief Financial Officer | DDisposition to issuer Performance-Based Restricted Stock Unitsderivative | -3,125 | $0.00 | $0 | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Alfred J Ford Jr Chief Commercial Officer | DDisposition to issuer Performance-Based Restricted Stock Unitsderivative | -11,250 | $0.00 | $0 | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Robert McNamara director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | $36.90 | $369k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Raymond W Cohen Chief Executive Officer | DDisposition to issuer Performance-Based Restricted Stock Unitsderivative | -31,125 | $0.00 | $0 | 0 | Nov 15, 2024 |
| Nov 15, 2024 | David M Demski director | DDisposition to issuer Stock Options (Right to buy)derivative | -10,000 | $19.30 | $193k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Robert McNamara director | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,333 | $33.85 | $113k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Michael H Carrel director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | $50.15 | $502k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Karen Noblett Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,963 | $56.81 | $168k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | John Woock EVP, Chief Mktg/Strtgy Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -15,555 | $56.81 | $884k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Alfred J Ford Jr Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,655 | $45.18 | $210k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Rinda Sama Chief Operating Officer | DDisposition to issuer Performance-Based Restricted Stock Unitsderivative | -13,125 | $0.00 | $0 | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Raymond W Cohen Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -196,451 | $56.81 | $11M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | nancy lynn snyderman MD director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | $49.96 | $500k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Rinda Sama Chief Operating Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -11,019 | $56.81 | $626k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | John Woock EVP, Chief Mktg/Strtgy Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -3,581 | $45.18 | $162k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Raymond W Cohen Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -106,776 | $69.37 | $7.4M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Karen Noblett Chief Medical Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -6,348 | $45.18 | $287k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Robert McNamara director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,000 | $56.20 | $281k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Rinda Sama Chief Operating Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -9,962 | $45.18 | $450k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Karen Noblett Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -11,998 | $69.37 | $832k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | Rinda Sama Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,294 | $69.37 | $437k | 0 | Nov 15, 2024 |
| Nov 7, 2024 | nancy lynn snyderman MD director | GGift Common Stock | -5,000 | $0.00 | $0 | 14,944 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Michael H Carreldirector, ceo, president, officer
- Raymond W CohenChief Executive Officer
- David M Demskidirector
- Alfred J Ford JrChief Commercial Officer
- Kari Leigh KeeseChief Financial Officer
- Jane E Kiernandirector
- Esteban Lopezdirector
- Robert McNamaradirector
- Karen NoblettChief Medical Officer
- Rinda SamaChief Operating Officer
- John WoockEVP, Chief Mktg/Strtgy Officer
- nancy lynn snyderman MDdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.